[HTML][HTML] Nirmatrelvir/ritonavir for patients with SARS-CoV-2 infection and impaired kidney function during the Omicron surge
J Yan, H Cai, J Wang, M Zhu, P Li, P Li, B Wu… - Frontiers in …, 2023 - frontiersin.org
Background: Nirmatrelvir/ritonavir has demonstrated effectiveness in high-risk patients with
coronavirus disease 2019 (COVID-19). However, investigations on the efficacy and safety of …
coronavirus disease 2019 (COVID-19). However, investigations on the efficacy and safety of …
[HTML][HTML] Comparison of safety and efficacy between Nirmatrelvir-ritonavir and molnupiravir in the treatment of COVID-19 infection in patients with advanced kidney …
WM Chu, EYF Wan, ZCT Wong, AR Tam… - …, 2024 - thelancet.com
Background Nirmatrelvir-ritonavir is used in patients with coronavirus disease 2019 (COVID-
19) with normal or mild renal impairment (eGFR≥ 30 ml/min per 1.73 m 2). There is limited …
19) with normal or mild renal impairment (eGFR≥ 30 ml/min per 1.73 m 2). There is limited …
Effectiveness and safety of nirmatrelvir-ritonavir in kidney transplant recipients with severe kidney dysfunction infected with COVID-19
H Yang, X Yu, W Hou, X Liu, J Chen… - Antimicrobial Agents …, 2024 - Am Soc Microbiol
Transplant patients face an elevated risk of coronavirus disease 2019 (COVID-19) morbidity
and mortality and commonly encounter renal dysfunction. Nirmatrelvir is primarily excreted …
and mortality and commonly encounter renal dysfunction. Nirmatrelvir is primarily excreted …
Early experience with modified dose nirmatrelvir/ritonavir in dialysis patients with coronavirus disease 2019
S Hiremath, PG Blake, A Yeung… - Clinical Journal of the …, 2023 - journals.lww.com
Background Nirmatrelvir/ritonavir was approved for use in high-risk outpatients with
coronavirus disease 2019 (COVID-19). However, patients with severe CKD were excluded …
coronavirus disease 2019 (COVID-19). However, patients with severe CKD were excluded …
Safety profile and clinical and virological outcomes of nirmatrelvir-ritonavir treatment in patients with advanced chronic kidney disease and coronavirus disease 2019
Background Nirmatrelvir-ritonavir is currently not recommended in patients with an
estimated glomerular filtration rate (eGFR)< 30 mL/minute/1.73 m2. Methods To determine …
estimated glomerular filtration rate (eGFR)< 30 mL/minute/1.73 m2. Methods To determine …
[HTML][HTML] Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
J Lu, H Cai, Y Hao, Z Lin, S Liu, Y Zhan… - Frontiers in …, 2023 - frontiersin.org
Background: Hemodialysis patients have a high risk of severe/critical COVID-19 and related
high mortality, but nirmatrelvir/ritonavir is not recommended for hemodialysis patients with …
high mortality, but nirmatrelvir/ritonavir is not recommended for hemodialysis patients with …
Pharmacokinetics of oral nirmatrelvir/ritonavir, a protease inhibitor for treatment of COVID‐19, in subjects with renal impairment
SS Toussi, JM Neutel, J Navarro… - Clinical …, 2022 - Wiley Online Library
Nirmatrelvir coadministered with ritonavir is highly efficacious in reducing the risk of
coronavirus disease 2019 (COVID‐19) adverse outcomes among patients at increased risk …
coronavirus disease 2019 (COVID‐19) adverse outcomes among patients at increased risk …
[HTML][HTML] Safety, efficacy, and relapse of nirmatrelvir-ritonavir in kidney transplant recipients infected with SARS-CoV-2
A Devresse, S Briol, J De Greef, F Lemaitre… - Kidney international …, 2022 - Elsevier
Introduction The efficacy of nirmatrelvir-ritonavir (NR; Paxlovid, Pfizer, New York, NY) to
decrease the risk of progression to severe COVID-19 in high-risk patients has been …
decrease the risk of progression to severe COVID-19 in high-risk patients has been …
Clinical effectiveness of oral antiviral agents for treating non-hospitalized COVID-19 patients with chronic kidney disease
CC Chen, CY Huang, JY Wu, MY Liu… - Expert Review of Anti …, 2024 - Taylor & Francis
Objectives This study examined the effectiveness of nirmatrelvir plus ritonavir (NMV-r) and
molnupiravir (MOV) in treating COVID-19 among chronic kidney disease (CKD) patients …
molnupiravir (MOV) in treating COVID-19 among chronic kidney disease (CKD) patients …
Pharmacokinetics of nirmatrelvir and ritonavir in COVID-19 patients with end-stage renal disease on intermittent hemodialysis
T Lingscheid, M Kinzig, A Krüger, N Müller… - Antimicrobial Agents …, 2022 - Am Soc Microbiol
Nirmatrelvir/ritonavir is an effective antiviral therapy against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). Use is not recommended in patients with end-stage …
syndrome coronavirus 2 (SARS-CoV-2). Use is not recommended in patients with end-stage …